Counselors in Westville, NJ Accepting Medicare
5 Counselors found. Showing 1 - 5
 Harold Williams, MHS,LCADC,CCS,CSW Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 227 Broadway, Westville, NJ 08093 Phone: 856-637-3144 |
 Ms. Terra Green Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 306 Chestnut Ln, Westville, NJ 08093 Phone: 856-535-0358 |
Christiana Tackie Counselor Medicare: Not Enrolled in Medicare Practice Location: 137 Florence Ave, Westville, NJ 08093 Phone: 856-899-8195 |
Rebekah Perez, LAC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1170 Delsea Dr, Westville, NJ 08093 Phone: 484-326-2292 |
Philip Michael Huber, LPC, ACS, LCADC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1170 Delsea Dr # 1145, Westville, NJ 08093 Phone: 856-506-9084 Fax: 856-853-0919 |
News Archive
U.N. officials recognize International Day of the Midwife
U.N. officials, recognizing the International Day of the Midwife on Thursday, lauded the efforts of midwives worldwide and "called for greater investment to ensure their life-saving services are available to all who need them around the world," the U.N. News Centre reports.
Researchers identify mechanism through which mitochondria control breast tumor aggressiveness
Doctors currently struggle to determine whether a breast tumor is likely to shift into an aggressive, life-threatening mode-an issue with profound implications for treatment. Now a group from The Scripps Research Institute (TSRI) has identified a mechanism through which mitochondria, the powerhouses of a cell, control tumor aggressiveness.
Bruker to purchase preclinical imaging product portfolio and related assets from Carestream
Carestream Health and Bruker have entered into an agreement for Bruker to purchase the preclinical in-vivo imaging equipment product portfolio and related assets from Carestream's Molecular Imaging business. Financial terms of the agreement are not being disclosed.
Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology
Prana Biotechnology has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world's leading medical journals, The Lancet Neurology.
› Verified 5 days ago